Impact of clinical and biochemical factors on alcohol withdrawal syndrome outcomes
IImpact of Clinical and Biochemical Variables on Mortality and Morbidity of Patients With Alcohol Withdrawal Syndrome Under Treatment According to the CIWA-AR Scale"
This study looks at how different health factors, like age and liver function, affect how long people with alcohol withdrawal syndrome experience symptoms and how well they recover.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 195 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Hospital General de Mexico Government |
| Locations | 1 site (Mexico City) |
| Trial ID | NCT06589973 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze how various clinical and biochemical variables affect the duration of symptoms and overall morbidity and mortality in patients experiencing Alcohol Withdrawal Syndrome (AWS). By reviewing clinical records from patients treated in the Department of Internal Medicine over a five-year period, the study seeks to identify risk factors such as age, alcohol consumption history, and liver function that may influence patient outcomes. The primary focus is to establish a relationship between these factors and the severity of AWS symptoms, measured in days of symptoms and hospital stay.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with Alcohol Withdrawal Syndrome who have clinical records available for review.
Not a fit: Patients with a history of seizures, chronic liver failure, or those who have not received sedative treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients undergoing alcohol withdrawal, potentially reducing morbidity and mortality.
How similar studies have performed: While there have been studies examining various factors in alcohol withdrawal, this specific observational approach focusing on clinical and biochemical variables is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical records of patients, both genders, over 18 years of age with Alcohol Withdrawal Syndrome according to the criteria for alcohol withdrawal. * Clinical records of candidates for admission for neurological monitoring and with criteria for use of sedative drugs according to the CIWA-Ar scale * Clinical records of patients containing the CIWA-Ar scale score at diagnosis Exclusion Criteria: * Clinical records of patients who already have a history of seizures or epilepsy * Clinical records of diabetic patients with diabetic ketoacidosis * Clinical records of patients who have not received any type of sedative treatment * Clinical records of patients with chronic liver failure or liver cirrhosis * Clinical records of patients with chronic liver disease with signs of hepatic encephalopathy * Clinical records of patients with related toxic-alcoholic hepatitis * Clinical records of patients with a life expectancy of less than 24 hours due to associated complications such as head trauma or other associated complications * Clinical records of patients who require intubation and mechanical ventilation upon admission * Clinical records of patients who have a vascular event that modifies the neurological evaluation * Clinical records of patients who before admission show psychomotor alteration or neurological deterioration that modifies the neurological evaluation such as the presence of Wernicke's encephalopathy
Where this trial is running
Mexico City
- Hospital General de Cuautitlan "General José Vicente Villada" — Mexico City, Mexico (Recruiting)
Study contacts
- Study coordinator: Christian O Ramos Peñafiel, PhD
- Email: leukemiachop33@gmail.com
- Phone: 5527892000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.